October 13, 2026

Alopecia therapy gains FDA breakthrough status

The designation covers an investigational botanical treatment for moderate-to-severe alopecia areata in patients aged 2 years and older.

MDSpire News

October 12, 2026

CDC: Measles cases surpass 4,000 in 2026

CDC data show that 96% of cases are outbreak-associated, with adults accounting for 40% of cases, up from 29% in 2025.

MDSpire News

October 09, 2026

FDA approves pritelivir for refractory HSV lesions

In a phase 3 trial, complete lesion healing occurred in 63% of patients receiving pritelivir vs. 34% receiving comparator treatments.

MDSpire News

October 09, 2026

CDC flags neuro symptoms after unapproved botulinum toxin

None of the 3 symptomatic patients knew the injected product lacked FDA approval.

MDSpire News

October 07, 2026

FDA approves first therapy for symptomatic dermographism

The oral BTK inhibitor produced a complete hive response in 29.3% of treated patients at week 12.

MDSpire News

September 25, 2026

FDA monthly preview: Key October decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News

September 15, 2026

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

MDSpire News

August 31, 2026

Do antihistamines help atopic dermatitis?

First-generation H1 antihistamines likely increase cognitive impairment, with cognitive effects differing among second-generation antihistamines.

MDSpire News

August 28, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

MDSpire News

August 28, 2026

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

MDSpire News